4,080 Shares in Guardant Health, Inc. $GH Acquired by Praxis Investment Management Inc.

Key Points

• Praxis Investment Management Inc. has acquired 4,080 shares of Guardant Health, valued at approximately $212,000, indicating strong institutional interest in the company.
• In recent insider trading, CEO Helmy Eltoukhy sold 300,000 shares for about $17.8 million, while a director significantly decreased their ownership by selling 2,165 shares.
• Analysts have raised price targets for Guardant Health, with Leerink Partners boosting their target from $70 to $75, reflecting strong confidence in the stock's future performance.

Praxis Investment Management Inc. purchased a new position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 4,080 shares of the company's stock, valued at approximately $212,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Signaturefd LLC raised its stake in Guardant Health by 50.5% during the 2nd quarter. Signaturefd LLC now owns 635 shares of the company's stock worth $33,000 after buying an additional 213 shares during the period. American Century Companies Inc. increased its holdings in Guardant Health by 0.3% during the 1st quarter. American Century Companies Inc. now owns 104,206 shares of the company's stock worth $4,439,000 after purchasing an additional 282 shares in the last quarter. IFP Advisors Inc increased its holdings in Guardant Health by 120.1% during the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company's stock worth $33,000 after purchasing an additional 334 shares in the last quarter. HighTower Advisors LLC increased its holdings in Guardant Health by 0.9% during the 1st quarter. HighTower Advisors LLC now owns 51,107 shares of the company's stock worth $2,177,000 after purchasing an additional 469 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in Guardant Health by 25.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company's stock worth $112,000 after purchasing an additional 537 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, Director Medina Manuel Hidalgo sold 2,165 shares of the stock in a transaction on Friday, September 12th. The stock was sold at an average price of $54.16, for a total transaction of $117,256.40. Following the completion of the transaction, the director directly owned 851 shares of the company's stock, valued at approximately $46,090.16. This represents a 71.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Helmy Eltoukhy sold 300,000 shares of the stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total value of $17,835,000.00. Following the transaction, the chief executive officer directly owned 2,123,499 shares of the company's stock, valued at approximately $126,242,015.55. This trade represents a 12.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 302,549 shares of company stock valued at $17,975,121. 6.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

GH has been the subject of a number of recent research reports. Leerink Partners boosted their price objective on Guardant Health from $70.00 to $75.00 and gave the stock an "outperform" rating in a report on Thursday, September 25th. JPMorgan Chase & Co. boosted their price objective on Guardant Health from $60.00 to $70.00 and gave the stock an "overweight" rating in a report on Thursday, September 25th. BTIG Research set a $80.00 price objective on Guardant Health in a report on Thursday, September 25th. Guggenheim boosted their price objective on Guardant Health from $56.00 to $67.00 and gave the stock a "buy" rating in a report on Thursday, September 25th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Guardant Health in a report on Wednesday, October 8th. Twenty-three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $65.86.

Guardant Health Stock Down 3.0%

GH stock opened at $65.46 on Monday. The firm has a market cap of $8.16 billion, a PE ratio of -19.54 and a beta of 1.53. The business has a 50 day moving average of $61.06 and a 200-day moving average of $50.96. Guardant Health, Inc. has a 12-month low of $20.14 and a 12-month high of $68.23.

Guardant Health (NASDAQ:GH - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.08. The business had revenue of $232.09 million during the quarter, compared to the consensus estimate of $211.19 million. The business's revenue was up 31.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.84) earnings per share. Guardant Health has set its FY 2025 guidance at EPS. On average, research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.